Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in arms of the study, in which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) followed by the addition of narlaprevir, 85-87 percent of patients achieved rapid virologic response (RVR), compared to 58-75 percent of patients in the no lead-in narlaprevir arms and no patients in the PEGINTRON and REBETOL control arm. RVR, defined in this study as undetectable virus (HCV RNA) at week 4 of narlaprevir treatment, is recognized as an important predictor for achieving sustained virologic response. These interim results from the NEXT-1 study were reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.[1]

"These interim results, while preliminary, are very encouraging, and showed that narlaprevir has potent antiviral activity in hepatitis C," said John Vierling, M.D., professor of medicine and surgery, chief of hepatology, Baylor College of Medicine, Houston, and the lead investigator of the study. "In this study, once-daily narlaprevir greatly improved viral clearance at week 4 of treatment in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Importantly, patients in the lead-in narlaprevir arms also achieved improved rates of early virologic response (EVR), defined as undetectable virus at week 12 of treatment, with 85-87 percent of patients having undetectable
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , September 3, 2015 ... compounds, Organosulfurs, Organic acids, Phenolics, and Others) and by ... beverage, Paints & coatings, and Others) - Global Trends ... segments the Biocides Market with an analysis and forecast ... value. Browse   88 tables and ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... artificial implants used to replace, augment, or repair ... a wide range of applications including cosmetic, spinal, ... are made of different materials such as polymers, ... the global implantable medical devices market to grow ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 The quantum ... industry, and the key market based on the product includes ... solar cell, chip, sensor, lighting, battery and energy storage, QD ... of different applications for the quantum dot market. The report ... North America , Europe ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5Global Implantable Medical Devices Market 2015-2019 2Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2
... 2011 University Hospitals (UH) Seidman Cancer Center, ... opens to patients on June 6. The ten-story, ... treatments and technology – all in a patient-centered, ... ) The $260 million, 375,000-square-foot hospital ...
... N.J., June 6, 2011 Bayer HealthCare Pharmaceuticals Inc. ... pharadin in SYM ptomatic P rostate ... which is exclusively licensed from Algeta ASA, in patients ... its primary endpoint by significantly improving overall survival.  Based ...
Cached Medicine Technology:University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 2University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 3Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 2Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 3
(Date:9/3/2015)... ... September 03, 2015 , ... ... cost increases for fully insured employer-sponsored health insurance plans, more employers are moving ... according to data released from the 2014 United Benefit Advisors (UBA) Health Plan ...
(Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters Welcomes ... to announce the additional of Carol Wysham, MD, to their esteemed Board of ... Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... responsibility concierges; simplifying responsibilities which can impact the delicate life balance between work ... situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency ...
(Date:9/3/2015)... NJ (PRWEB) , ... September 03, 2015 , ... ... today that AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s solution for ... been named a “KMWorld 2015 Trend-Setting Product”. This is the fifth consecutive ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... Administration on Wednesday called for new warnings on the labels ... of a slight increased risk of heart disease and diabetes ... announced in May that it was reviewing the prostate cancer ...
... tomography colonography (CTC) otherwise known as virtual colonoscopy ... colorectal cancer (CRC) screening rates, according to a study ... of Roentgenology ( www.ajronline.org ). ... the U.S. "While colonoscopy is currently the preferred test ...
... and engineers from around the world will gather on the ... discuss some of the latest breakthroughs in lasers and optics ... materials, and medicine. Journalists are invited to Frontiers in ... of the Optical Society (OSA), which is being held together ...
... (HealthDay News) -- A hormone receptor normally confined to the ... parts of the body, researchers report. Researchers from the ... with French government scientists, say this common link may offer ... cancer. They evaluated tumor tissue samples from 1,336 men ...
... A common virus that can cause coughing and ... the ability to kill cancer. Harnessing that power, researchers ... Medical Center, are conducting a clinical trial to see if ... By the age of five, most people have been exposed ...
... A new British study reveals why leopards have spots. ... cats to a mathematical model of pattern development in order ... cats, markings. Patterning -- especially irregular or complex patterns ... live in dense habitats, in the trees, and are active ...
Cached Medicine News:Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 2Health News:FDA Calls for New Warnings on Some Prostate Cancer Drugs 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:New Tumor Marker May Improve Cancer Detection: Study 2Health News:A redeeming role for a common virus 2
9 mm wide tip. 35 mm from angle to tip....
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Medicine Products: